Latest News & Updates
Corey Langer, MD, discussed the therapeutic potential for anti-HER2 agents in non–small cell lung cancer in a presentation at the 2015 International Lung Cancer Congress.
A number of clinical trials are now assessing PD-1 and PD-L1 inhibitors in combination with chemotherapy, targeted therapies, and radiation therapy in an attempt to further improve outcomes for patients with non–small cell lung cancer.
Paul Bunn, MD, discussed the latest translational advances in NSCLC at the 2015 International Lung Cancer Congress.
Highly effective next-generation therapies are currently in development for patients with oncogene-driven non–small cell lung cancer, specifically those with alterations in EGFR, ALK, ROS1, NTRK, or a variety of other gene.
John C. Byrd, MD, discusses receiving the American Society of Hematology’s 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.
Latest Peer Exchange Discussions
In this segment, Diane Reidy Lagunes, MD; J. Philip Boudreaux, MD; Rodney Pommier, MD; and Pamela L. Kunz, MD, explain available diagnostic strategies for pancreatic neuroendocrine tumors. View Now
John L. Marshall, MD, and Cathy Eng, MD, share key points to consider when interacting with patients with colorectal cancer and discussing management of their disease. View Now
Thomas D. Coates, MD, outlines the benefits and limitations of blood transfusions in patients who experience complications associated with sickle cell disease. View Now
In this segment, Rodney Pommier, MD; J. Philip Boudreaux, MD; Pamela L. Kunz, MD; and Diane Reidy Lagunes, MD, describe the biology of pancreatic neuroendocrine tumors. View Now
Most Popular Right Now
Online CME Activities